Dr John Liddell is a Chief Technologist at CPI Biologics based in Darlington, UK. The CPI is a Research and Technology Organisation and is part of the UK Catapult network. CPI Biologics supports UK activities in advanced bioprocessing covering a wide range of advanced therapy products including viral vectors, RNA/LNP products, and exosomes, as well as biopharmaceutical products such as antibodies, non-antibody proteins, VLPs and vaccines. He provides support to biopharmaceutical development to increase access to new therapies through the application of innovative technologies.
Prior to CPI, John’s previous experience involved the development and manufacture of biotherapeutics, working in senior process development roles with global organisations, including Fujifilm Diosynth Biotechnologies, Merck &Co, Avecia Biologics, Zeneca and ICI.
He has almost 30 years of experience in bioprocessing with experience encompassing all phases of bioprocess development from early phase process definition to late phase process validation and commercial production